Genentech exec appointments
Executive Summary
Hal Barron, MD, will head Genentech's newly formed development organization combining the medical affairs and developmental sciences departments. He was previously VP-medical affairs, and will continue to report to Chief Medical Officer Susan Hellmann, MD. Patrick Yang, PhD, joins Genentech from Merck as VP-South San Francisco manufacturing and engineering, reporting to Senior VP-Product Operations David Ebersman. At Merck, Yang was VP-Asia/Pacific Manufacturing Operations. Both positions are newly created...
You may also be interested in...
Genentech CFO
Genentech CFO Lou Lavigne will retire in March 2005 after serving as a Genentech finance exec for over 22 years. He first served as controller and was promoted to CFO in 1988. In his retirement, Lavigne intends to serve on the boards of other companies. Senior VP-Product Operations David Ebersman will replace Lavigne as CFO. Pat Yang, PhD, who serves as VP-South San Francisco manufacturing & engineering, will be promoted to senior VP-product operations. Yang joined the company from Merck in late 2003 (1"The Pink Sheet" Jan. 19, 2004, In Brief)...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.